Clinical trial registry record

Adversity and Its Association With the Development and Expression of Rheumatic Diseases

A registered study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Unknown.
Evidence
Registered phase not reported study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated May 3, 2024.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT06386380
Last registry update
May 3, 2024
Status
Unknown
Phase
Phase not reported
Sponsor
National Institute of Medical Sciences and Nutrition, Salvador Zubiran
Enrollment
110
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase not reported
Study design
OBSERVATIONAL
Evidence population
Human clinical study registration
Participants
110
Population
ALL · 18 Years to 100 Years
Duration
2024-06-01 to 2026-02-01
Intervention
Rheumatic diseases Mistreatment Scale (RDMS); Routine assessment of patient index data 3 (RAPID-3); Health Assessment Questionnaire (HAQ); WHOQOL-BREF; Depression, Anxiety and Stress Scale (DASS-21); Brief Resilient Coping Scale; Expression of CDKN2A /p16INK4a; Immunophenotype of leukocyte subpopulations; Telomere length; Cellular senescence
Comparator
Not reported
Outcomes measured
Adversity and senescence in patients with rheumatoid arthritis — At inclusion (baseline moment) (cross-sectional study)]; Eexpression of the p16INK4a gene in CD3+ — At inclusion (baseline moment) (cross-sectional study)]; Telomere length — At inclusion (baseline moment) (cross-sectional study)]
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase not reportedA trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Senolytics · 100%Abstract contains controlled term: cellular senescence. Source terminology contains: cellular senescence. Abstract supplies longevity context: senescence. Study type is explicitly identified as OBSERVATIONAL.

Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.

senolytics
Open primary sourceExport JSON